In regard to PD-1 rs11568821 polymorphism, the findings indicated that this variant significantly decreased the overall cancer risk in heterozygous (OR = 0.79, 95% CI = 0.67–0.94, p = 0.006, AG vs. GG) and dominant (OR = 0.82, 95% CI = 0.70–0.96, p = 0.020, AG+AA vs. GG) genetic models (Table 3). The gene discussed is PDCD1; the disease is cancer.